LCL 161

Drug Profile

LCL 161

Alternative Names: LCL-161; NVP-LCL161; Second Mitochondria-derived Activator of Caspases (SMAC) mimetic - Novartis Oncology; SMAC mimetic LCL161

Latest Information Update: 15 May 2017

Price : $50

At a glance

  • Originator Novartis
  • Developer Mayo Clinic; National Cancer Institute (USA); Novartis; Novartis Oncology; SCRI Development Innovations; US Oncology Research
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Inhibitor of apoptosis protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Multiple myeloma; Myelofibrosis
  • Phase I/II Ovarian cancer; Small cell lung cancer
  • Phase I Cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 28 Apr 2017 Chemical structure information added
  • 01 Apr 2017 Pharmacodynamics and pharmacokinetics data from a preclinical trial in Solid tumours presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 22 Mar 2017 Novartis plans a phase I trial of CJM 112 or LCL 161 in combination with PDR 001 and CJM 112 alone for Multiple myeloma (Second-line therapy) (NCT03111992)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top